Literature DB >> 25010798

Mechanisms of trauma-induced coagulopathy.

Jessica C Cardenas1, Charles E Wade, John B Holcomb.   

Abstract

PURPOSE OF REVIEW: Hemorrhage is the leading cause of potentially preventable death following injury. Excessive and uncontrolled bleeding, commonly referred to as trauma-induced coagulopathy (TIC), affects a quarter of all trauma patients and is associated with substantial injuries, increased transfusion requirements, and poor outcomes. Recent data have contributed to our current understanding of the molecular mechanisms driving TIC. RECENT
FINDINGS: The current literature offers evidence supporting proposed mechanisms that induce TIC, such as platelet dysfunction, endogenous anticoagulation, endothelial activation, fibrinogen modifications, and hyperfibrinolysis. However, the majority of these data are mere associations; causative data are slowly unfolding through the utilization of animal models of hemorrhagic shock coupled with prospective observational clinical studies.
SUMMARY: As both clinical and basic science research expands our understanding of TIC, trauma patient care is improving substantially. Future studies should focus on the interplay between the coagulation pathways whose simultaneous or codependent dysregulation could offer the most advantageous points for intervention.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25010798     DOI: 10.1097/MOH.0000000000000063

Source DB:  PubMed          Journal:  Curr Opin Hematol        ISSN: 1065-6251            Impact factor:   3.284


  9 in total

1.  S2'-subsite variations between human and mouse enzymes (plasmin, factor XIa, kallikrein) elucidate inhibition differences by tissue factor pathway inhibitor -2 domain1-wild-type, Leu17Arg-mutant and aprotinin.

Authors:  K Vadivel; Y Kumar; G I Ogueli; S M Ponnuraj; P Wongkongkathep; J A Loo; M S Bajaj; S P Bajaj
Journal:  J Thromb Haemost       Date:  2016-11-19       Impact factor: 5.824

2.  Nonhuman primate model of polytraumatic hemorrhagic shock recapitulates early platelet dysfunction observed following severe injury in humans.

Authors:  Leasha J Schaub; Hunter B Moore; Andrew P Cap; Jacob J Glaser; Ernest E Moore; Forest R Sheppard
Journal:  J Trauma Acute Care Surg       Date:  2017-03       Impact factor: 3.313

Review 3.  Is Coagulopathy an Appropriate Therapeutic Target During Critical Illness Such as Trauma or Sepsis?

Authors:  Hunter B Moore; Robert D Winfield; Mayuki Aibiki; Matthew D Neal
Journal:  Shock       Date:  2017-08       Impact factor: 3.454

Review 4.  The emerging therapeutic potential of extracellular vesicles in trauma.

Authors:  Nijmeh Alsaadi; Amudan J Srinivasan; Anupamaa Seshadri; Matthew Shiel; Matthew D Neal; Melanie J Scott
Journal:  J Leukoc Biol       Date:  2021-09-17       Impact factor: 6.011

5.  A Review of Radiation-Induced Coagulopathy and New Findings to Support Potential Prevention Strategies and Treatments.

Authors:  Ann R Kennedy; Amit Maity; Jenine K Sanzari
Journal:  Radiat Res       Date:  2016-07-26       Impact factor: 2.841

Review 6.  Optimizing transfusion strategies in damage control resuscitation: current insights.

Authors:  Timothy H Pohlman; Alison M Fecher; Cecivon Arreola-Garcia
Journal:  J Blood Med       Date:  2018-08-20

7.  Identification of injury and shock driven effects on ex vivo platelet aggregometry: A cautionary tale of phenotyping.

Authors:  Nichole E Starr; Zachary A Matthay; Alexander T Fields; Brenda Nunez-Garcia; Rachael A Callcut; Mitchell J Cohen; Lucy Zumwinkle Kornblith
Journal:  J Trauma Acute Care Surg       Date:  2020-07       Impact factor: 3.697

8.  Traumatic Endotheliopathy: A Prospective Observational Study of 424 Severely Injured Patients.

Authors:  Pär I Johansson; Hanne H Henriksen; Jakob Stensballe; Mikkel Gybel-Brask; Jessica C Cardenas; Lisa A Baer; Bryan A Cotton; John B Holcomb; Charles E Wade; Sisse R Ostrowski
Journal:  Ann Surg       Date:  2017-03       Impact factor: 12.969

9.  Enhanced Antifibrinolytic Efficacy of a Plasmin-Specific Kunitz-Inhibitor (60-Residue Y11T/L17R with C-Terminal IEK) of Human Tissue Factor Pathway Inhibitor Type-2 Domain1.

Authors:  Kanagasabai Vadivel; Anne K Zaiss; Yogesh Kumar; Frank M Fabian; Ayman E A Ismail; Mark A Arbing; Wallace G Buchholz; William H Velander; S Paul Bajaj
Journal:  J Clin Med       Date:  2020-11-17       Impact factor: 4.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.